CEO & Co-Founder
Shlomo is the Co-Founder and CEO of SK-Pharma Group, a global pharmaceutical company that manufactures, sells, and markets generic, specialty pharma, hybrid generics and biosimilar pharmaceutical products in over 18 countries. Additionally, Shlomo is the CEO of Arphio, an orphan drug company, which promote, market and sales orphan drugs in rest of the world utilizing a unique technological proprietary. Shlomo holds over 17 years of experience in the pharmaceutical industry, with a main focus on leveraging technology to define and improve business procedures. Shlomo has developed a global strategic alliance with over 200 leading companies that share the same innovative and technology driven mindset. SK-Pharma had launched over 300 products worldwide, majority of which were first-to-market and branded products. Shlomo capabilities to leverage technological features in fast and applicable manner is what lead he’s organization to be the fastest growing pharmaceutical group in Israel and beyond. Shlomo attained a Master’s degree in Global Management by Salford University in the UK, and has also recently completed a Doctorate in Business Administration, with specialization in public health,  from the Royal Academy of Economics and Technology in Switzerland.